Cristal Therapeutics is a clinical stage biopharmaceutical company developing tissue-
targeted nanomedicines based on its proprietary CriPec® polymeric nanoparticle technology platform for the treatment of cancer and other diseases with high unmet patient need and considerable commercial potential.
The company is looking for proprietary oligonucleotides having therapeutic potential that they can in-license and develop to the market in combination with their CriPec® platform. The therapeutic candidate needs to fit some criteria.
Check the pdf file to know more about this opportunity.Download the RFP